{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047566","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.516065+00:00","generated_at":"2026-05-21T16:50:39.091242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3","bullets":["Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.","Cash $4.6M at March 31, 2025, up from $3.7M at year-end 2024 after two offerings raising ~$3.6M gross.","Closed $2.5M registered direct offering in Jan 2025 and $1.1M offering in Mar 2025; $12M Lincoln Park equity line closed in May.","Received positive EMA regulatory guidance for ibezapolstat Phase 3 program, aligned with FDA, confirming MAA pathway.","Japanese and Indian patent offices granted new DNA polymerase IIIC inhibitor patents expiring Dec 2039 for ACX-375C."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047566","json":"https://secwatch.observer/filing/0001104659-25-047566.json","markdown":"https://secwatch.observer/filing/0001104659-25-047566.md","text":"https://secwatch.observer/filing/0001104659-25-047566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925047566/0001104659-25-047566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465925047566/tm2514876d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:50:39.091242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}